Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedMay 31, 2023EPINEPHrine added to dextrose 5%Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0701-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0700-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0699-2023Class IITerminatedMay 31, 2023Neonatal PN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0698-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0697-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0696-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0695-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0694-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0693-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0692-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0691-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0690-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0689-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0688-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0687-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0686-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0685-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0684-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0683-2023Class IITerminatedMay 31, 2023Neonatal TPN Starter BagLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0682-2023Class IITerminatedMay 31, 2023Modified del Nido MicroplegiaLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0681-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0680-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0679-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0678-2023Class IITerminatedMay 31, 2023Microplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0677-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0676-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0675-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0674-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0673-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0672-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0671-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0670-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0669-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0668-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0667-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0666-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0665-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0664-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0663-2023Class IITerminatedMay 31, 2023Cardioplegia SolutionLack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.Central Admixture Pharmacy Services, Inc. · D-0662-2023